Benign prostatic hyperplasia (BPH) is an extremely common disease of older men which leads to morbidity by obstructing urine outflow. There is a considerable body of evidence implicating increased estrogen, in conjunction with androgens, as an underlying factor in the etiology of BPH, but the mechanism by which these hormonal alterations lead to BPH is unclear. The investigators have shown increased expression of FGF7 and FGF2 in BPH that is correlated with epithelial and stromal proliferation, respectively. The role of androgens and estrogens in controlling FGF7 and FGF2 production in the prostate is either controversial or unknown. They have also shown that paracrine factors secreted by prostatic epithelial cells can stimulate production of FGFs by prostatic stromal cells. For FGF7 this paracrine factor is IL- 1alpha. FGF 17, which can increase proliferation of fibroblastic cells, is also expressed by prostatic epithelial cells. Their hypothesis is that increases in estrogen, in combination with androgen, can synergistically stimulate FGF2 and FGF7 production by stromal cells in BPH, which can be further stimulated by local, epithelial derived paracrine factors that both induce FGF production and enhance proliferation of FGF producing stromal cells. They propose two Specific Aims:
Specific Aim 1 : Control of FGF7 and FGF2 expression by androgens and estrogens: Using primary cultures of human stromal cell they will assess the effect of androgens, estrogens, and paracrine epithelial factors, alone or in combination, on FGF7 and FGF2 production. They will then determine the mechanism by which FGF protein expression is increased in response to the inducing factors. Finally, they will evaluate the effects of androgens and estrogens on FGF production and proliferation using an in vivo model system in which human tissue is implanted in scid/hpg mice.
Specific Aim 2 : Control of FGF7 and FGF2 expression by paracrine epithelial factors: Their first goal is to correlate expression of IL- Ialpha with expression of FGF7 to test their hypothesis that FGF7 production can be driven by IL- 1alpha. In vivo they will derive a transgenic mouse line that expresses IL- 1alpha at high concentrations in the prostate and determine whether there is induction of FGF7 expression in parallel with hyperplasia of the prostate. The second goal is to identify the epithelial derived paracrine factor(s) which induces FGF2 production by stromal cells. Their final goal is to define the role of FGF 17 as an epithelial derived paracrine inducer of stromal cell proliferation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK054170-06
Application #
6523711
Study Section
Special Emphasis Panel (ZRG1-UROL (01))
Program Officer
Mullins, Christopher V
Project Start
1997-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
6
Fiscal Year
2002
Total Cost
$224,250
Indirect Cost
Name
Baylor College of Medicine
Department
Pathology
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Castro, Patricia; Xia, Chen; Gomez, Lori et al. (2004) Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60:153-9
Polnaszek, Nathaniel; Kwabi-Addo, Bernard; Wang, Jianghua et al. (2004) FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia. Prostate 60:18-24
Castro, Patricia; Giri, Dipak; Lamb, Dolores et al. (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55:30-8
Giri, D; Ozen, M; Ittmann, M (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159:2159-65
Giri, D; Ittmann, M (2001) Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 159:139-47
Giri, D; Ittmann, M (2000) Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 157:249-55
Giri, D; Ropiquet, F; Ittmann, M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063-71
Ropiquet, F; Giri, D; Lamb, D J et al. (1999) FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 162:595-9
Giri, D; Ropiquet, F; Ittmann, M (1999) FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 180:53-60